Celcuity Inc. (CELC): Price and Financial Metrics
GET POWR RATINGS... FREE!
CELC Stock Price Chart Interactive Chart >
CELC Price/Volume Stats
| Current price | $8.06 | 52-week high | $14.78 |
| Prev. close | $8.25 | 52-week low | $4.81 |
| Day low | $7.79 | Volume | 7,500 |
| Day high | $8.35 | Avg. volume | 56,920 |
| 50-day MA | $9.79 | Dividend yield | N/A |
| 200-day MA | $8.82 | Market Cap | 124.61M |
Celcuity Inc. (CELC) Company Bio
Celcuity LLC, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. It develops CELx tests to diagnose breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is based in Minneapolis, Minnesota.
Latest CELC News From Around the Web
Below are the latest news stories about CELCUITY INC that investors may wish to consider to help them evaluate CELC as an investment opportunity.
Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium/ Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for cancer treatment, today announced that an abstract accepted for a Spotlight Poster presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS) is now available on the SABCS website. |
Needham Sticks to Its Buy Rating for Celcuity (CELC)In a report released today, Gil Blum from Needham reiterated a Buy rating on Celcuity (CELC - Research Report), with a price target of $25.00. The company's shares closed yesterday at $10.00.Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Geron, and Rocket Pharmaceuticals. According to TipRanks, Blum has an average return of -22.4% and a 29.02% success rate on recommended stocks. Celcuity has an analyst consensus of Moderate Buy, with a price target consensus of $25.00.See Insiders’ Hot Stocks on TipRanks >> Based on Celcuity's latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $9. |
Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select ConferenceCelcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in one-on-one and small group meetings at the 13th Annual Craig-Hallum Alpha Select Conference in New York on Thursday, November 17, 2022. |
Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateCelcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, today announced financial results for the third quarter ended September 30, 2022 and other recent business developments. |
Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call/ Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, today announced that it will release its financial results for the third quarter 2022 after the stock market close on Thursday, November 10, 2022. Management will host a webcast/teleconference the same day at 4:30 p.m. |
CELC Price Returns
| 1-mo | -19.32% |
| 3-mo | -8.51% |
| 6-mo | 5.91% |
| 1-year | -39.58% |
| 3-year | -25.65% |
| 5-year | -55.20% |
| YTD | -38.89% |
| 2021 | 44.00% |
| 2020 | -13.91% |
| 2019 | -55.65% |
| 2018 | 26.60% |
| 2017 | N/A |
Loading social stream, please wait...